Quick Answer
Emergent BioSolutions Inc. reported Revenue (ASC 606) of $742.90 million for fiscal year 2025.
Emergent BioSolutions Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $742.90M | -28.8% |
| 2024 | $1.04B | -0.5% |
| 2023 | $1.05B | -32.5% |
| 2020 | $1.56B | +40.6% |
| 2019 | $1.11B | +41.4% |
| 2018 | $782.40M | +39.5% |
| 2017 | $560.90M | +14.8% |
| 2016 | $488.80M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $231.10M | -21.3% | +64.0% |
| June 30, 2025 | $140.90M | -44.7% | -36.6% |
| March 31, 2025 | $222.20M | -26.0% | -24.4% |
| September 30, 2024 | $293.80M | — | +15.4% |
| June 30, 2024 | $254.70M | — | -15.2% |
| March 31, 2024 | $300.40M | — | -24.4% |
| June 30, 2021 | $397.50M | +0.7% | +15.9% |
| March 31, 2021 | $343.00M | +78.2% | -11.0% |
- Emergent BioSolutions Inc. showed a decrease of -28.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Emergent BioSolutions Inc.’s revenue (asc 606) has grown by 52.0% (from $488.80 million to $742.90 million).
- The most recent figure is from Emergent BioSolutions Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: